PEAR THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | 0.00% |
|
0.00% | 0.00% |
| Mar. 22 | Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc. | CI |
| Mar. 04 | Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc. | CI |
Presenter SpeechJudah Frommer (Analysts)Hi. Good afternoon, everyone, and welcome to the final...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Pear Therapeutics, Inc. is a commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O. The Company's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Companyâs pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas. The Company has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions.
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 142 | |
| +33.01% | 50.85B | |
| +0.05% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +11.18% | 26.11B | |
| -21.74% | 19.13B | |
| +8.55% | 13.05B | |
| +27.91% | 12.16B | |
| +24.30% | 12.08B |
- Stock Market
- Equities
- PEARQ Stock
- News Pear Therapeutics, Inc.
- Transcript : Pear Therapeutics, Inc. Presents at Credit Suisse 31st Annual Healthcare Conference, Nov-08-2022 03